Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECORNASDAQ:GUTSNASDAQ:LNSRNASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$5.09-5.2%$5.77$4.47▼$19.49$37.77M0.7997,134 shs67,050 shsGUTSFractyl Health$2.06-5.1%$1.61$0.87▼$6.18$100.89M1.85326,688 shs290,851 shsLNSRLENSAR$12.50$13.67$3.50▼$17.31$147.40M0.5282,408 shs57,825 shsRCELAVITA Medical$5.54-4.5%$7.69$5.31▼$14.16$146.45M1.55184,144 shs568,065 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore-5.21%-11.17%+10.41%-40.54%-21.81%GUTSFractyl Health-5.07%+3.52%+34.20%+60.94%-66.23%LNSRLENSAR0.00%-4.65%-11.85%-17.38%+156.15%RCELAVITA Medical-4.48%-9.33%-17.19%-35.20%-37.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECORelectroCore2.816 of 5 stars3.52.00.00.03.32.50.6GUTSFractyl Health2.3044 of 5 stars3.52.00.00.03.50.00.0LNSRLENSAR1.4019 of 5 stars2.03.00.00.02.82.50.0RCELAVITA Medical1.5355 of 5 stars3.40.00.00.03.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 3.00Buy$25.50400.98% UpsideGUTSFractyl Health 3.00Buy$11.00433.98% UpsideLNSRLENSAR 2.00Hold$15.0020.00% UpsideRCELAVITA Medical 2.75Moderate Buy$16.50197.83% UpsideCurrent Analyst Ratings BreakdownLatest ECOR, RCEL, LNSR, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.004/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/10/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/4/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.003/18/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$26.46M1.43N/AN/A$1.24 per share4.10GUTSFractyl Health$60K1,681.54N/AN/AN/A∞LNSRLENSAR$57.07M2.58N/AN/A$2.97 per share4.21RCELAVITA Medical$71.66M2.04N/AN/A$0.17 per share32.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$18.83M-$1.56N/AN/AN/A-54.40%-154.45%-69.16%8/6/2025 (Estimated)GUTSFractyl Health-$77.09M-$1.85N/AN/AN/A-64,849.48%N/A-57.21%8/13/2025 (Estimated)LNSRLENSAR-$14.38M-$4.85N/A∞N/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)RCELAVITA Medical-$61.85M-$2.19N/AN/AN/A-96.26%-337.91%-71.50%8/6/2025 (Estimated)Latest ECOR, RCEL, LNSR, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/8/2025Q1 2025RCELAVITA Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 million5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A2.121.87GUTSFractyl Health0.605.585.57LNSRLENSARN/A3.372.10RCELAVITA Medical9.392.832.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%GUTSFractyl HealthN/ALNSRLENSAR40.15%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipECORelectroCore19.70%GUTSFractyl HealthN/ALNSRLENSAR38.52%RCELAVITA Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore507.42 million5.35 millionNot OptionableGUTSFractyl Health10248.98 millionN/AN/ALNSRLENSAR11011.79 million7.14 millionOptionableRCELAVITA Medical13026.44 million25.74 millionOptionableECOR, RCEL, LNSR, and GUTS HeadlinesRecent News About These CompaniesCantor Fitzgerald Comments on AVITA Medical FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comCantor Fitzgerald Predicts AVITA Medical FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comAVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral CapitalJune 6, 2025 | marketbeat.comAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™June 5, 2025 | finance.yahoo.comAVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough AwardsJune 3, 2025 | globenewswire.comShort Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 23.9%June 3, 2025 | marketbeat.comDelta Investment Management LLC Increases Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)May 22, 2025 | marketbeat.comCantor Fitzgerald Comments on AVITA Medical FY2025 EarningsMay 16, 2025 | marketbeat.comAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live TodayMay 13, 2025 | finance.yahoo.comAVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet ChallengesMay 12, 2025 | seekingalpha.comAnalysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest ReportMay 11, 2025 | finance.yahoo.comAVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAVITA Medical Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAVITA Medical to Announce First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comAVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025April 9, 2025 | globenewswire.com6 Analysts Assess AVITA Medical: What You Need To KnowApril 6, 2025 | nasdaq.comAvita Medical announces U.S. commercial launch of CohealyxApril 4, 2025 | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3, 2025 | globenewswire.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comAvita Medical amends PermeaDerm distribution agreement with Stedical ScientificMarch 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?Broadcom Earnings Preview: AVGO Stock Near Record HighsBy Leo Miller | June 3, 2025View Broadcom Earnings Preview: AVGO Stock Near Record Highse.l.f. Beauty Sees Record Surge After Earnings, Rhode DealBy Leo Miller | May 30, 2025View e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealECOR, RCEL, LNSR, and GUTS Company DescriptionselectroCore NASDAQ:ECOR$5.09 -0.28 (-5.21%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.18 +0.09 (+1.87%) As of 06/13/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Fractyl Health NASDAQ:GUTS$2.06 -0.11 (-5.07%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.11 +0.05 (+2.43%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.LENSAR NASDAQ:LNSR$12.50 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$12.52 +0.02 (+0.16%) As of 06/13/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.AVITA Medical NASDAQ:RCEL$5.54 -0.26 (-4.48%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.52 -0.01 (-0.27%) As of 06/13/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
